08:02 AM EDT, 03/26/2024 (MT Newswires) -- Stoke Therapeutics ( STOK ) shares surged nearly 99% in recent Tuesday premarket activity after reporting Monday that STK-001 was generally "well-tolerated" across phase 1/2a and open label extension studies to treat Dravet syndrome as there were "no clinical manifestations" observed during the trials. TD Cowen also upgraded the stock to outperform from market perform.

Check-Cap ( CHEK ) shares were up more than 56% a day after it signed a definitive business combination agreement with Nobul AI, a fintech firm.

Mesoblast (MESO) stock was up over 23% after it said late Monday the US Food and Drug Administration has indicated that the available clinical data from a phase 3 study appears to be adequate to support the submission of a proposed Biologics License Application for remestemcel-L.

Invivyd ( IVVD ) stock jumped 15% after Morgan Stanley upgraded it to overweight from equalweight and raised its price target to $10 from $4.

McCormick ( MKC ) stock rose nearly 6% after reporting higher fiscal Q1 adjusted earnings and net sales from a year earlier.

Price: 12.91, Change: +6.41, Percent Change: +98.62